Published in Osteoporos Int on July 19, 2005
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int (2006) 1.21
A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int (2013) 0.94
Hospitalisations for fracture and associated costs between 2000 and 2009 in Ireland: a trend analysis. Osteoporos Int (2012) 0.90
The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord (2012) 0.84
Profile of teriparatide in the management of postmenopausal osteoporosis. Int J Womens Health (2010) 0.82
Using common random numbers in health care cost-effectiveness simulation modeling. Health Serv Res (2013) 0.75
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 12.60
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Value Health (2003) 6.02
Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health (2004) 4.98
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab (2000) 3.68
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res (1999) 3.08
Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int (2000) 2.99
The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int (2001) 2.81
The components of excess mortality after hip fracture. Bone (2003) 2.63
Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ (2000) 2.27
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16
Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med (1996) 2.05
Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone (2000) 1.89
Evaluation and treatment of low back pain: an evidence-based approach to clinical care. Muscle Nerve (2003) 1.78
Hip fractures: a worldwide problem today and tomorrow. Bone (1993) 1.72
Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int (2001) 1.66
Accounting for future costs in medical cost-effectiveness analysis. J Health Econ (1997) 1.41
Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int (2000) 1.35
Cost-equivalence of different osteoporotic fractures. Osteoporos Int (2003) 1.33
Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone (2002) 1.30
The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand (1997) 1.27
The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res (2003) 1.19
A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int (1999) 1.18
Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics (2003) 1.02
The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Econ (2002) 1.00
Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int (1999) 0.99
Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int (1995) 0.86
[Cost-effectiveness of bisoprolol in chronic heart failure]. Lakartidningen (2002) 0.81
A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care (1999) 0.79
Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl (1996) 0.79
Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int (2002) 0.78
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Epidemiology of fractures in England and Wales. Bone (2001) 5.76
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Perspective. How many women have osteoporosis? J Bone Miner Res (1992) 4.99
Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet (2006) 4.95
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Radiographic patterns of osteoarthritis of the knee joint in the community: the importance of the patellofemoral joint. Ann Rheum Dis (1992) 4.79
Use of oral corticosteroids and risk of fractures. J Bone Miner Res (2000) 4.75
EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2000) 4.37
Bone density screening for osteoporosis. Lancet (1990) 3.87
Defining osteoarthritis of the hip for epidemiologic studies. Am J Epidemiol (1990) 3.77
Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int (2009) 3.74
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Cohort profile: the Hertfordshire cohort study. Int J Epidemiol (2005) 3.62
Bone densitometry in clinical practice. BMJ (1995) 3.48
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int (2002) 3.45
Complete genomic sequence and analysis of the prion protein gene region from three mammalian species. Genome Res (1998) 3.44
A prospective randomised trial of internal fixation versus arthroplasty for displaced fractures of the neck of the femur. Functional outcome for 450 patients at two years. J Bone Joint Surg Br (2002) 3.40
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int (2001) 3.23
Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis (1993) 3.16
Fluoride in drinking water and risk of hip fracture in the UK: a case-control study. Lancet (2000) 3.16
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Knee pain and disability in the community. Br J Rheumatol (1992) 3.15
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Exercise during growth and bone mineral density and fractures in old age. Lancet (2000) 3.06
Pectin esterification is spatially regulated both within cell walls and between developing tissues of root apices. Planta (1990) 3.03
GP job satisfaction in 1987, 1990 and 1998: lessons for the future? Fam Pract (2000) 2.99
Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int (2000) 2.99
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum (2003) 2.94
An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int (2001) 2.94
Maternal vitamin D status during pregnancy and child outcomes. Eur J Clin Nutr (2007) 2.94
The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int (2001) 2.81
Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int (2012) 2.81
Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) (2007) 2.81
Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int (1997) 2.80
The prevalence of urinary incontinence in women in four European countries. BJU Int (2004) 2.75
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Back pain in Britain: comparison of two prevalence surveys at an interval of 10 years. BMJ (2000) 2.73
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
A global representation of vitamin D status in healthy populations. Arch Osteoporos (2012) 2.69
Osteoarthritis of the hip: an occupational disease in farmers. BMJ (1992) 2.69
The components of excess mortality after hip fracture. Bone (2003) 2.63
Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res (2000) 2.55
Occupational physical activities and osteoarthritis of the knee. Arthritis Rheum (2000) 2.54
Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS Study Group. European Prospective Osteoporosis Study Group. Osteoporos Int (2000) 2.52
Manual handling activities and risk of low back pain in nurses. Occup Environ Med (1995) 2.48
Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int (2012) 2.48
Use of statins and risk of fractures. JAMA (2001) 2.47
Prospective cohort study of predictors of incident low back pain in nurses. BMJ (1997) 2.46
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest (1987) 2.40
Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium. Osteoarthritis Cartilage (2010) 2.39
Projecting the need for hip replacement over the next three decades: influence of changing demography and threshold for surgery. Ann Rheum Dis (1999) 2.36
Trends in admissions for hip fracture in England and Wales, 1968-85. BMJ (1990) 2.35
Knee osteoarthritis and obesity. Int J Obes Relat Metab Disord (2001) 2.30
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum (2006) 2.28
How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum (2008) 2.27
Risk of fractures in patients with multiple sclerosis: a population-based cohort study. Neurology (2012) 2.25
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
Vertebral fractures predict subsequent fractures. Osteoporos Int (1999) 2.24
Dietary calcium, physical activity, and risk of hip fracture: a prospective study. BMJ (1989) 2.24
A multicentre randomized controlled trial of epidural corticosteroid injections for sciatica: the WEST study. Rheumatology (Oxford) (2005) 2.23
Acetabular dysplasia and hip osteoarthritis in Britain and Japan. Br J Rheumatol (1998) 2.22
Bacterial arthritis in an English health district: a 10 year review. Ann Rheum Dis (1986) 2.21
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11,050 men. HIV Med (2008) 2.19
Vitamin D and skeletal health in infancy and childhood. Osteoporos Int (2014) 2.16
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) (2000) 2.13
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int (2004) 2.11
Physical activity at 36 years: patterns and childhood predictors in a longitudinal study. J Epidemiol Community Health (1992) 2.11
The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) (2005) 2.11
Conservative treatment of acute low-back pain. A prospective randomized trial: McKenzie method of treatment versus patient education in "mini back school". Spine (Phila Pa 1976) (1990) 2.01
Use of oral corticosteroids in the United Kingdom. QJM (2000) 1.95
Are rates of ageing determined in utero? Age Ageing (1998) 1.95
Will elderly rest home residents wear hip protectors? Age Ageing (1998) 1.95
Muscle strength, activity, housing and the risk of falls in elderly people. Age Ageing (1989) 1.94
Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone (2000) 1.89
Radiographic assessment of osteoarthritis in population studies: whither Kellgren and Lawrence? Osteoarthritis Cartilage (1993) 1.88
Studies on the role of the morphological constituents of the microsome fraction from rat liver in protein synthesis. Biochem J (1964) 1.86
Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol (1998) 1.85
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Physical activity and calcium intake in fracture of the proximal femur in Hong Kong. BMJ (1988) 1.83